Type2 Diabetes Clinical Trial
Official title:
KETOCOGNITION - Effects of Ketone Bodies on Cognition in Type 2 Diabetes
Diabetes negatively affects cognition and increases the risk of developing overt dementia.
Decreased cerebral glucose metabolism may be contributing to this effect, thus providing a
glucose substitute using ketone bodies might improve neuronal function.
In this study the investigators propose to provide quantitative results on cognitive
performance during acute hyperketonemia in patients with type 2 diabetes.
It has been proposed that hypometabolism in the brain contributes to the neuropathology that
leads to Alzheimer's disease (AD). Additionally cognitive disturbances in patients with AD
are associated with and paralleled by a decrease in cerebral glucose metabolism. This AD-like
reduction in cerebral metabolism has also been associated with insulin-resistance, and may
contribute to one of the links between diabetes and AD. Therefore manipulating
neuro-energetics by providing a glucose substitute seems to be a means of improving neuronal
function.
Here the investigators will examine the effect of ketone bodies on cognitive performance in
patients with type 2 diabetes by a randomized cross-over trial. Each subject will meet for
two experimental visits separated by 2-6 weeks. During the two visit days subjects will, in a
randomized order, receive ketone bodies (β-hydroxybutyrate) or placebo (saline)
intravenously. On both test days plasma glucose levels will be clamped. After glucose levels
have been stabilized cognitive performance will be assessed by a battery of validated
cognitive tests.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
| Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
| Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
| Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
| Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
| Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
| Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
| Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
| Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
| Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
| Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
| Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
| Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
| Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
| Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
| Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
| Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
| Active, not recruiting |
NCT04451837 -
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
|
Phase 2 |